Opposite effects of native and oxidized lipoproteins on the activity of secretory phospholipase A2 group IIA

Prostaglandins and Other Lipid Mediators

Volumn 90, Issue 1-2, 2009, Pages 37-41

  Korotaeva, Aleksandra A ^a   Samoilova, Elena V ^a   Pirkova, Aleksandra A ^a   Ameliushkina, Vera A ^a   Prokazova, Nina V ^a   Tkachuk, Vsevolod A ^a   Chazov, Eugeny I ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Human blood serum; Native lipoproteins; Oxidized lipoproteins; Regulation; Secretory phospholipase A2

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SECRETORY PHOSPHOLIPASE A2; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; PATHOGENESIS; SERUM;

GROUP II PHOSPHOLIPASES A2; HEART NEOPLASMS; HUMANS; INFLAMMATION; LIPOPROTEINS; MYXOMA; OXIDATION-REDUCTION;

EID: 70350022227     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.07.004     Document Type: Article

References (34)

1. Nevalainen T.J., Graham G.G., and Scott K.F. Antibacterial actions of secreted phospholipases A2. Biochim Biophys Acta 1781 1-2 (2008) 1-9
2. Hack C.E., Wolbink G.J., Schalkwijk C., Speijer H., Hermens W.T., and van den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 18 3 (1997) 111-115
3. Chen W., Li L., Zhu J., et al. Control of angiogenesis by inhibitor of phospholipase A2. Chin Med Sci J 19 1 (2004) 6-12
4. Tribler L., Jensen L.T., Jorgensen K., et al. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue. Anticancer Res 27 5A (2007) 3179-3185
5. Webb N.R. Secretory phospholipase A2 enzymes in atherogenesis. Curr Opin Lipidol 16 3 (2005) 341-344
6. Boekholdt S.M., Keller T.T., Wareham N.J., et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 25 (2005) 839-846
7. Jönsson-Rylander A.C., Lundin S., Rosengren B., Pettersson C., and Hurt-Camejo E. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 10 3 (2008) 252-259
8. Niessen H.W., Krijnen P.A., Visser C.A., Meijer C.J., and Erik Hack C. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?. Cardiovasc Res 60 1 (2003) 68-77
9. Oestvang J., and Johansen B. PhospholipaseA2: a key regulator of inflammatory signaling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta 1761 11 (2006) 1309-1316
10. Fichtlscherer S., Kaszkin M., Breuer S., Dimmeler S., and Zeiher A.M. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. Clin Sci (Lond) 106 5 (2004) 511-517
11. Nijmeijer R., Meuwissen M., Krijnen P.A., et al. Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction. Eur J Clin Invest 38 4 (2008) 205-210
12. Mallat Z., Steg P.G., Benessiano J., Tanguy M.L., Fox K.A., Collet J.P., et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 46 7 (2005) 1249-1257
13. Mallat Z., Benessiano J., Simon T., et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 27 5 (2007) 1177-1183
14. Korotaeva A.A., Samoilova E.V., Kaminny A.I., et al. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL. Mol Cell Biochem 270 1-2 (2005) 107-113
15. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 9 (1955) 1345-1353
16. Lowry O.H., Roseborough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
17. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Res Commun 6 (1989) 67-75
18. Skamrov A.V., Nechaenko M.A., Goryunova L.E., et al. Gene expression analysis to identify mRNA markers of cardiac myxoma. J Mol Cell Cardiol 37 3 (2004) 717-733
19. Skipski V.P., Barclay M., Barclay R.K., Fetzer V.A., Good J.J., and Archibald F.M. Lipid composition of human serum lipoproteins. Biochem J 104 2 (1967) 340-352
20. Boyanovsky B.B., and Webb N.R. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther 23 (2009) 61-72
21. Matsumoto T., Kobayashi T., and Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14 30 (2007) 3209-3220
22. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., and Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 12 1 (2006) RA5-16
23. Murakami M., Kudo I., and Inoue K. Secretory phospholipases A2. J Lipid Mediat Cell Signal 12 2-3 (1995) 119-130
24. Koumanov K.S., Momchilova A.B., Quinn P.J., and Wolf C. Ceramides increase the activity of the secretory phospholipase A2 and alter its fatty acid specificity. Biochem J 363 (2002) 45-51
25. Koumanov K., Wolf C., and Béreziat G. Modulation of human type II secretory phospholipase A2 by sphingomyelin and annexin VI. Biochem J 15 326 Pt 1 (1997) 227-233
26. Gesquiere L., Cho W., and Subbaiah P.V. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 41 15 (2002) 4911-4920
27. Nakajima K., Nakano T., and Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 367 1-2 (2006) 36-47
28. Paradis M.E., Hogue M.O., Mauger J.F., et al. Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL. Int J Obes (Lond) 30 11 (2006) 1615-1622
29. Krijnen P.A., Meischl C., Nijmeijer R., Visser C.A., Hack C.E., and Niessen H.W. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?. Cardiovasc Hematol Disord Drug Targets 6 2 (2006) 113-123
30. Divchev D., Grothusen C., Luchtefeld M., et al. Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J 29 16 (2008) 1956-1965
31. Pirkova A.A., Samoilova E.V., Ameliushkina V.A., et al. Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease. Kardiologiia (Russian) 47 4 (2007) 37-40
32. Leite J.O., Vaishnav U., Puglisi M., Fraser H., Trias J., and Fernandez M.L. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc Disord 9 (2009) 7
33. Zeiher B.G., Steingrub J., Laterre P.F., Dmitrienko A., Fukiishi Y., and Abraham E. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. EZZI Study Group. Crit Care Med 33 8 (2005) 1741-1748
34. Bradley J.D., Dmitrienko A.A., Kivitz A.J., et al. A randomized, double-blinded, placebo- controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 32 3 (2005) 417-423